Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats by unknown
Ning et al. Lipids in Health and Disease  (2015) 14:31 
DOI 10.1186/s12944-015-0030-5RESEARCH Open AccessLipid metabolism and inflammation modulated
by Vitamin D in liver of diabetic rats
Conghua Ning1, Lina Liu1, Guodong Lv2, Ye Yang1, Yuanyuan Zhang1, Rui Yu1, Yongtao Wang1 and Jun Zhu1*Abstract
Background: In recent years, much evidence suggested that vitamin D plays an important role in decreasing the
risk of type 2 diabetes. The purpose of this study was to investigate whether 1, 25 (OH) 2D3 can modulate
inflammation and lipid metabolism in type 2 diabetic rat liver.
Methods: Type 2 diabetes was induced in SD rat with high-fat and high-sugar diets and multiple low-dose
streptozotocin. The levels of serum calcium, phosphorus, glucose, TC, TG, AST, ALT and hepatic TG were determined.
H & E staining were performed to assess the effects of vitamin D treatment on pathological changes in the liver
tissues. Immunohistology, real-time PCR and Western blot were used to evaluate the expressions of NF-κ B,
MCP-1, ICAM-1, TGF-β1, PPAR-α and CPT-1.
Results: The administration of 1, 25 (OH) 2D3 reduced liver weight. Compared to DM rats, 1, 25 (OH) 2D3-treated DM rats
had lower liver weight. Moreover, compared to healthy or 1, 25 (OH) 2D3-treated DM rats, DM rats had increased hepatic
transcription factors (NF-κ B), monocyte chemoattractant protein −1 (MCP-1), intercellular adhesion molecule −1 (ICAM-1),
transforming growth factor-β1 (TGF-β1) expressions, but had fewer hepatic PPAR- α and CPT-1 expressions.
Conclusions: 1, 25 (OH) 2D3 significantly modulated the liver inflammation and lipid metabolism in diabetic rat models,
which may be caused by its regulations on hepatic signaling NF-κ B pathway and PPAR- α.
Keywords: Diabetes-induced liver injury, Vitamin D, NF-κ B, PPAR-αIntroduction
Type 2 diabetes mellitus (T2DM) is one of the main non-
communicable chronic diseases with a growing preva-
lence; it affected 382 million people worldwide in the year
of 2013 and is expected to affect 592 million by 2035.
Chronic complications of diabetes, which involve coronary
artery disease, renal, liver and ophthalmologic diseases, is
the primary cause of disability and mortality in diabetes
mellitus (DM) patients. It is reported that the standardized
mortality rate from end-stage liver disease (i.e. cirrhosis) is
higher than that for cardiovascular disease among patients
with diabetes [1,2]. Liver disease is one of diabetic compli-
cations, and should be well addressed [3].
Vitamin D is a fat-soluble vitamin, which is an essential
micronutrient with major implications for human health
[4]. The biologically active form of vitamin D is 1, 25
(OH) 2D3 (also known as active vitamin D3 [5]. Vitamin D* Correspondence: zhujun6677@163.com
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[6]. Macrophages and dendrite cells constitutively express
Vitamin D receptors, which indicates vitamin D plays an
important role in regulating the inflammatory response
[7,8]. Several studies have confirmed the involvement of
vitamin D in modulating the inflammatory response
[9,10]. In recent years, much evidence suggested that vita-
min D plays an important role in decreasing the risk of
many chronic diseases, including type 2 diabetes [11], the
metabolic syndrome [12] and cardiovascular disease [13].
Diabetes-induced liver injury includes inflammatory
response, lipid accumulation and liver fibrosis [14].
T2DM produces a state of chronic hyperglycemia and
insulin resistance, which leads to the increasing of intra-
cellular reactive oxygen species (ROS) levels. The accu-
mulated ROS can activate the NF-κ B pathway, leading
to the occurrence of liver inflammation [15]. Previous
study demonstrated that vitamin D reduces the nuclear
translocation of NF-κ B by up-regulating the inhibitor of
NF-κ B (I κ B-α) in LPS-stimulated murine macrophageshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ning et al. Lipids in Health and Disease  (2015) 14:31 Page 2 of 9[16]. However, the regulatory effect of 1, 25 (OH) 2D3 on
NF-κ B and its downstream inflammatory cytokines expres-
sions in DM hepatocyte remains unclear. In addition, the
accumulation of triglycerides within hepatic cell is the
mainly characteristic of fatty liver with type 2 diabetes [17].
Peroxisome proliferator-activated receptor α (PPAR-α),
which is mainly expressed in the liver, plays a pivotal role in
the regulation hepatic lipid metabolism [18]. Motiwala [19]
and Zittermann [20] have shown that vitamin D modulates
lipid metabolism by decreasing the level of serum triglycer-
ide (TG) in overweight subjects. A recent study have found
that 1, 25 (OH) 2D3 modulates cardiac lipid metabolism by
affecting the expression of PPAR-α in a DM rat model [21].
It has not yet been studied whether vitamin D can modu-
late hepatic lipid metabolism by regulating PPAR-α in type
2 diabetic rat liver.
Increasing evidence suggests that the circulating con-
centration of 25-OH vitamin D was negatively associated
with the risk of liver disease [22,23]. However, given that
the regulatory mechanisms of 1, 25 (OH) 2D3 on liver
have not been completely elucidated, the purpose of this
study was to investigate whether 1, 25 (OH) 2D3 can
modulate inflammation and lipid metabolism in type 2
diabetic rat liver.
Materials and methods
Animal modeling and grouping
The experimental designs and protocols for animal
studies were reviewed and approved by Xinjiang man-
agement committee for medical laboratory animal sci-
ences. A total of 50 male SD rats were provided by the
Xinjiang Disease Control and Prevention Center. Rats
were housed in standard cages and maintained on rat
chow and tap water ad libitum. All rats were housed
for 1 week prior to diet intervention. We randomly se-
lected 15 rats as normal control group (NC group),
which were fed with normal diet. The remaining rats
were used to establish DM models. They were fed with
high-fat and high-sugar diets, containing 10% refiing
lard, 20% sucrose, 2% cholesterol, 8% custard powder,
and 60% of normal diet, for indicated duration (eight
weeks). Then these rats were subjected to the intraperi-
toneal injection of 35 mg/kg streptozotocin (STZ;
Sigma, St. Louis, MO, USA). One week later, the fasting
plasma glucose (FPG) and 2-h plasma glucose (2hPG)
were measured with a complete blood glucose monitor
(ACCU-CHEK, Germany), rats with FPG ≥ 7.0 mmol/L
and/or 2hPG ≥ 11.1 mmol/L were considered as DM
models.
These DM model rats were randomly divided into dia-
betic group (DM group) and vitamin D treatment group
(VD group, n = 15 per group). Rats of vitamin D treat-
ment group were administrated vitamin D (0.03 μg/kg
body weight; Shanghai Roche Pharmaceuticals, Shanghai,China) in 0.05 mL peanut oil once daily via gavage, and
equivalent peanut oil was administrated in diabetic group
and normal control group for 8 weeks. At the end of the
vitamin D intervention period, blood samples were drawn
from the abdominal aorta and the serum samples were
separated by centrifuge. The entire liver was dissected out,
weighed, the tissues were cut into small pieces, immersed
in RNA later solution at room temperature, and then
stored at −80°C. Remaining liver tissues were fixed in 4%
paraformaldehyde.
Biochemical analysis
Serum calcium (Ca), phosphorus (P), glucose total choles-
terol (TC), TG, Alanine aminotransferase (ALT), aspartate
aminotransferase (AST), were determined with an auto-
matic biochemistry analyzer (Hitachi 7600, Tokyo, Japan).
Hepatic TG contents were determined enzymatically by
using commercial kits (Bio Sino Bio-technology and Sci-
ence Inc, Beijing, China).
Histopathological staining
The fresh liver tissue was washed with saline, and then
fixed in 10% buffered formalin. After dehydrated, these
tissues were embedded with paraffin, and then cut into
3 μm sections on a microtome (Leica, Nussloch, Germany)
and then stained with H & E.
Immunohistochemistry
Paraffin sections were de-waxed and re-hydrated through
a graded alcohol series. The endogenous peroxidase was
removed, and the sections were exposed to antigen re-
trieval. Then, slides were incubated, respectively, with
Rabbit anti-rat MCP-1 (Boster Biological Technology,
Wuhan, Hubei, China), rabbit anti-rat ICAM-1 (Boster
Biological Technology, Wuhan, Hubei, China), rabbit anti-
rat TGF-β1 (Boster Biological Technology, Wuhan, Hubei,
China), and rabbit anti-rat CPT-1a (Bioss Biotechnology,
Beijing, China) (final concentrations 1:100, 1:100, 1:200,
1:100, respectively) for over-night at 4°C. Then the sec-
tions were then incubated with secondary antibodies.
After stained with DAB chromogenic reagent (ZSGB-BIO,
Beijing, China) and counterstained with hematoxylin,
these sections were sealed and then visualized under mi-
croscopy with the CM-2000B biomedicine image analysis
system (Beihang, Beijing, China). Brown staining was con-
sidered as positive. Five fields were randomly selected
under high magnification (×400), and the averaged num-
ber of positive cells were counted and calculated.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from liver tissue (100 mg) with
RNeasy Mini kits (Qiagen, Hilden, Germany). Quanti-
Tect Rev Transcription Kits (Qiagen) were used to
reverse-transcribed to cDNA, according to manufactures’
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formed with QuantiFast SYBR green PCR Master Mix
containing ROX as a passive reference (Qiagen), on
Bio-Rad iQ5 system (Bio-Rad, Hercules, CA, USA). Pri-
mer sequences used were listed in Table 1. Quantitative
PCR amplification conditions were as follows: melt at
95°C for 5 min; and at 95°C for 50 s, 60°C for 30 s, for
40 cycles. The housekeeping gene b-actin was used as a
reference gene for normalization. Primers used for rat
genes were as following: NF-κ B p65: F: 5′-TCA CGG
GAC CTG GCT GGG AG-3′,R: 5′-CCG CCG AAG
CTG CAT GGA CA-3′;MCP-1:F: 5′-CAG CCA GAT
GCA GTT AAT GCC-3′,R: 5′-AGC CGA CTC ATT
GGG ATC AT-3′;ICAM-1:F: 5′-CGT GGC GTC CAT
TTA CAC CT-3′,R: 5′-TTA GGG CCT CCT CCT
GAG C-3′; TGF-β1:F: 5′-AGA AGT CAC CCG CGT
GCT AAT-3′,R: 5′-CAC TGC TTC CCG AAT GTC
TGA-3′; PPAR-α: F: 5′-CCTGCCTTCCCTGTGAA
CT-3′,R:5′-ATCTGCTTCAAGTGGGGAGA-3′;CPT-1:
F:5′-GCCAGACGAAGAAC ATTG-3′,R: 5′-CCTTGAC-
CATAGCCA TCC-3′; β- actin: F: 5′-AGT ACC CCA TTG
AAC ACG GC-3′,R: 5′-TTT TCA CGG TTG GCC TTA
GG-3′. For each gene, relative change in steady state
Mrna in samples was determined using the ΔΔCt
method, corrected for the housekeeper.
Western blotting
Liver tissue was homogenized in RIPA Lysis Buffer con-
taining PMSF (a protease inhibitor), and Proteins were
collected by centrifuging at 12,000 turn at 4°C in centri-
fuge for 10 min. The protein concentration was mea-
sured by Bradford assay. About 50 micrograms of
protein were loaded on 5–10% gradient gels. Proteins
were transferred to a PVDF membrane (Thermo Scien-
tific) for 120 min at 80 V. The membranes were incu-
bated in blocking buffer for 2 hours. Then they were
incubated with different primary antibodies overnight at
4°C, washed with TBST and incubated with secondary
antibody for 2 h at room temperature. Antigen antibody
complexes were then visualized using Western Breeze
(invitrogen, USA).The primary antibodies used here in-
clude NF- k B p65(1:1000, Cell Signaling Technology)
and PPAR-α(1:1000, Cell Signaling Technology). The in-
tensity of protein bands were quantified using the Quan-
tity One software (Bio-Rad, USA).Table 1 Effects of 1,25(OH)2D3 on body and liver weight
Group Weight(g) Liver weight (g) Liver⁄Body
NC 461.71 ± 35 13.20 ± 1.2 2.86 ± 0.22
DM 346.14 ± 14* 24.37 ± 1.5* 7.05 ± 0.44*
VD 362.87 ± 16* 21.57 ± 1.6*# 5.96 ± 0.53*#
NC, normal control group; DM, diabetic group; VD, vitamin D treatment group.
Values are mean ± SD, n = 15 per group.
*P < 0 .05 vs. NC; #P < 0 .05 vs. DM.Statistical analysis
All quantitative data are expressed as the mean ± the
standard error of the mean (SEM). SPSS 17.0 software
was used for statistical analysis. Comparisons between
two groups were analyzed via t-test, and comparisons
between more than two groups were analyzed via one-
way ANOVA to identify differences among means.
Pearson correlations were adopted to note the correlation.
A value of P < 0.05 was considered statistically significant.
Result
Effect of 1,25(OH)2D3 and diabetes on body and liver
weight
About the final weight, rats of DM and VD group showed a
lower body weight compared to rats of NC group (P < 0.05),
whereas the body weight was similar between the DM
and VD group (P > 0.05, Table 1).
The liver weight was measured and showed a significant
increase in DM rats than those in NC rats (P < 0.05) , the
ratio of liver to body weight was still significantly higher.
The administration of 1,25 (OH) 2D3 led to a significant re-
duction in both liver weight and the ratio of liver to body
weigh 1,25 (OH) 2D3-treated DM rats compared to DM
rats (P < 0.05, Table 1).
Effect of 1,25 (OH) 2D3 on serum metabolic parameters
and hepatic TG
There was no significant difference in serum calcium
and phosphorus levels of all groups (P > 0.05). Serum
glucose level in DM and VD groups was significantly
higher than that in NC group (P < 0.05). Rats in the DM
group exhibited impaired metabolic function as shown
by increased serum triglyceride, TC. In the VD group, 1,
25 (OH) 2D3 reduced the level of serum TG, but not
serum TC. Our data showed that serum ALT and AST
concentrations were extremely elevated in rats of DM
group. In the VD group, 1, 25 (OH) 2D3 treatment sig-
nificantly lowered serum ALT and AST concentrations
compared with the DM group. The level of hepatic TG
in the DM group was significantly higher than that in
NC group (P < 0.05), In the VD group, 1, 25 (OH) 2D3
reduced the level of hepatic TG (Table 2).
1, 25 (OH) 2D3 attenuated diabetes-induced hepatic
damage
Liver pathology with H & E staining is presented in
Figure 1. The hepatic cell structure in normal control
group was normal and clear without inflammation and
necrosis. In the liver of DM group, diabetes increased
hepatic damage, and the morphological change was
obviously necrotic and/or inflammatory foci. However,
in the liver of 1, 25 (OH) 2D3-treated DM group, the mor-
phological change was less severe with less inflammatory
Table 2 Effects of 1,25(OH)2D3 on serum metabolic parameters and hepatic TG
Group Ca P Glucose TC TG ALT AST Hepatic TG
(mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (U/L) (U/L) (mg/g)
NC 2.57 ± 0.10 1.52 ± 0.11 5.61 ± 0.62 1.11 ± 0.09 0.86 ± 0.11 43.09 ± 7.6 69.86 ± 9.9 8.35 ± 1.34
DM 2.61 ± 0.13 1.55 ± 0.08 26.52 ± 3.62* 1.25 ± 0.14* 1.30 ± 0.09* 121.87 ± 14* 150.16 ± 12* 67.74 ± 8.89*
VD 2.63 ± 0.17 1.53 ± 0.08 26.09 ± 1.92* 1.29 ± 0.11* 1.11 ± 0.13*# 95.99 ± 16. *# 105.18 ± 15*# 31.72 ± 7.49*#
Ca, serum calcium; P, serum phosphorus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NC, normal control group; DM, diabetic group; VD,
vitamin D treatment group.
Values are mean ± SD, n = 15 per group.
*P < 0 .05 vs. NC; # P < 0 .05 vs. DM.
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group.
Increased NF-κ B and its downstream inflammatory
cytokines expression in liver tissues from the DM group
and suppressed by 1, 25 (OH) 2D3
To test whether hepatic NF-κ B signaling pathway in-
volves in the mechanism of diabetes-induced hepatic
damage, we examined their expression by different
methods. IHC staining for MCP-1, ICAM-1, and TGF-
β1 in livers from the DM group were both strongly posi-
tive, whereas they were almost negative in the normal
control group , the amount of brown staining granules
and the covered area were significantly decreased in the
1, 25 (OH) 2D3-treated DM group, compared with the
DM group (Figure 2). Western blot analysis showed that
hepatic NF-κ B protein levels in the DM group were sig-
nificantly increased compared with those of the normal
control group; 1, 25 (OH) 2D3 treatment significantly re-
duced NF-κ B protein levels compared with DM group
(Figure 3A), as was hepatic NF-κ B, MCP-1, ICAM-1,
and TGF-β1 mRNA (Figure 4). 1, 25 (OH) 2D3 adminis-
tration suppressed the expression of NF-κ B, MCP-1,
ICAM-1, and TGF-β1. Hepatic NF-κ B, MCP-1, ICAM-
1, and TGF-β1 mRNA levels of the 1,25 (OH) 2D3treated
DM group were all strongly reduced than those from theFigure 1 Effects of 1,25 (OH) 2D3 on liver histology. Histological analysis of
normal control group; DM, diabetic group; VD, vitamin D treatment group.DM group (Figure 4), as was hepatic NF-κ B protein
levels (Figure 3A).
1,25 (OH) 2D3 up-regulated the PPAR-α and CPT-1
expression, which involved in lipid oxidation
The cytokines involved in the regulation of hepatic lipid
b-oxidation were assessed by different methods. IHC
staining for PPAR-α and CPT-1 in livers from the nor-
mal control group were both strongly positive, whereas
the amount of brown staining granules and the covered
area were significantly decreased in the DM group. 1, 25
(OH) 2D3 treatment significantly increased the amount
of brown staining granules and the covered area com-
pared with DM group (Figure 2). Western blot analysis
showed that a drastic decrease in hepatic protein level of
PPAR-α was found in the DM group when compared to
that of normal control group, 1, 25 (OH) 2D3 treatment
reversed the expression of PPAR-α (Figure 3B), as was
hepatic PPAR-α and CPT-1 mRNA, 1, 25 (OH) 2D3 ad-
ministration up-regulated the expression of PPAR-α and
CPT-1 in liver (Figure 5).
Discussion
In the present study, we have demonstrated that 1, 25 (OH)
2D3 has protective effects on livers of diabetic rat by modu-
lating inflammation and lipid metabolism. Moreover, thesteatosis in liver sections stained with H & E (magnification 400 ×). NC,
Figure 2 Immunohistochemistry (IHC) staining for MCP-1, ICAM-1, TGF-β1, CPT-1. IHC staining for MCP-1 (A-C; ×400); IHC staining for ICAM-1
(D-F; ×400); IHC staining for TGF-β1 (G-I; ×400), IHC staining for CPT-1 (J-L; ×400). The averaged number of positive cells of MCP-1 (M), ICAM-1
(N), TGF-β1 (O), CPT-1 (P). NC, normal control group; DM, diabetic group; VD, vitamin D treatment group. *P < 0 .05 vs. NC; #P < 0 .05 vs. DM.
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Figure 3 Western blot analysis of protein expression NF-κ B and PPAR-α. Representative western blot images and quantitative analysis of NF-κ B
(A), PPAR-α (B). β-actin was used as a loading control. NC, normal control group; DM, diabetic group; VD, vitamin D treatment group. *P < 0 .05
vs. NC; #P < 0 .05 vs. DM.
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regulates the expression of the NF-κ B signaling pathway
and up-regulates the expression of PPAR-α to attenuate the
diabetes-induced liver injury.
Chronic inflammation is involved in the development of
hepatic disease [24,25].With the increasing severity of liver
disease, the expression of hepatic pro-inflammatory cyto-
kines also increased [26]. The transcription factor NF-κ B
and related mechanisms have gradually become a new hot
spot in related research field. Multiple studies have demon-
strated that the transcription factor NF-κ B play a crucial
role in the decision between life and death of a hepatocyte
[27]. It is the “genetic switch” of inflammation chain and
regulates the gene expression including cellular prolifera-
tion, the inflammatory response, chemokines and cell adhe-
sion molecules [28]. Cai D [29] reported that the activity of
NF-κ B in the diabetic liver was significantly higher. MCP-
1, which is produced mainly by macrophages and endothe-
lial cells, is a potent chemotactic factor for monocytes [30].
It is considered that MCP-1 was specifically activated by
NF-κ B in the presence of high glucose [31]. Several studies
have reported a correlation between blood and hepatic
levels of MCP-1 and the extent of inflammation both in hu-
man and animals [32,33]. Moreover, it is suggested that
MCP-1 contributes to liver fibrosis, independent of effects
on steatosis and inflammation [34]. ICAM-1 is a cytokine
responsive integral membrane receptor expressing on the
vascular endothelium, and it has been known to play an im-
portant role in the development of diabetic pathology [35].
HG-induced up-regulation of NF-κ B promotes ICAM-1
expression through PKC and mitogen-activated protein
kinase (MAPK) pathways [36]. TGF-β1 is a multifunctionalcytokine, it participates in inflammatory processes, induces
fibrosis, causes the suppression of immune response
[37,38]. Liver cells can produce TGF-β1, and it plays an im-
portant role in inflammation in the liver [39]. It was also
suggested that TGF-β1 is a potent profibrogenic factor se-
creted by activated HSCs, which contributes to the extra
cellular matrix (ECM) expression and liver fibrosis [40].
Our results showed that the expression of intra-hepatic
NF-κ B and its downstream inflammatory cytokines MCP-
1, ICAM-1, and TGF-β1 in DM group are significantly
higher than the normal control group, indicating that the
liver injury in diabetic rats may be partly associated with
the NF-κ B signaling pathway. Emerging data have demon-
strated that vitamin D has anti-inflammatory and antioxida-
tive effects in streptozotocin-induced diabetes [41]. In this
study, the effectiveness of 1, 25 (OH) 2D3 in attenuating the
increasing of NF-κ B, MCP-1, ICAM-1, and TGF-β1 in
liver of DM rats suggests that 1,25 (OH) 2D3 might serve as
an anti-inflammatory agent for DM liver disease.
On the other hand, hepatic steatosis is one of the mecha-
nisms of liver injury in diabetes. Previous investigation
showed that an impaired fatty acid oxidation can promote
the development of hepatic steatosis [18]. Hepatic lipid me-
tabolism is mainly regulated by several nuclear receptors
and transcription factors. Peroxisome proliferator-activated
receptor a (PPAR-α) is one of the major regulators in fatty
acid oxidation, prominently expressed in liver, heart and
skeletal muscle, which plays an important role in regulation
of genes that are involved in lipids utilization and storage
[42]. CPT-1 is a rate-limiting enzyme of mitochondria me-
diated fatty acids β-oxidation, which can facilitate the first
step of long-chain fatty acids entering into mitochondria.
Figure 5 Effects of 1,25 (OH) 2D3 on the expression of hepatic PPAR-α and the related genes CPT-1. The mRNA expression of hepatic PPAR-α and
related genes were assessed. The relative mRNA levels were determined by quantitative RT-PCR and normalized to β-actin. Each gene expression
was determined by the 2-ΔΔCt method. (A) The mRNA level of hepatic PPAR-α. (B) The mRNA level of CPT-1. Data are expressed as mean ± SD of each
group (n = 15 per group). NC, normal control group; DM, diabetic group; VD, vitamin D treatment group. *P < 0 .05 vs. NC; #P < 0 .05 vs. DM.
Figure 4 Effects of 1,25 (OH) 2D3 on the expression of hepatic NF-κ B and the related genes. The mRNA expression of hepatic NF-κ B and related
genes were assessed. The relative mRNA levels were determined by quantitative RT-PCR and normalized to β-actin. Each gene expression was determined
by the 2-ΔΔCt method. (A) The mRNA level of hepatic NF-κ B. (B) The mRNA level of MCP-1, (C) The mRNA level of hepatic ICAM-1, (D) The mRNA level
of hepatic TGF-β1. Data are expressed as mean ± SD of each group (n = 15 per group). NC, normal control group; DM, diabetic group; VD,
vitamin D treatment group. *P < 0 .05 vs. NC; #P < 0 .05 vs. DM.
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expression is under the regulation of PPAR-α [43,44]. It is
reported that PPAR-α-defective mice exhibit macrovesicu-
lar steatosis because of failing to induce fatty acid oxidation
in liver [45]. The expression of hepatic PPAR-a was signifi-
cantly decreased in the state of NAFLD [43]. PPAR-α ago-
nists was shown to prevent the development of steatosis by
promoting fatty acid oxidation [46]. To explore whether
the protective effects of 1, 25 (OH) 2D3 was related to
PPAR a activation, the expression of PPAR-α and its target
gene was assessed. Our results showed that the expression
of PPAR- α and CPT-1 was significantly declined in DM
group, whereas 1, 25 (OH) 2D3 increased the PPAR-α and
CPT-1 expression. Up-regulated PPAR-α by 1, 25 (OH) 2D3
in liver may promote β-oxidation and results in decreased
TG levels. CPT-1 was benefit for FFA transport into mito-
chondrial for further oxidation and thus decreased lipid de-
position. Our study only examined lipid profiles in serum
but not in liver tissues, because elevated serum cholesterol
and triglyceride concentrations are closely associated with
hyperglycemia and obesity. Our data suggested that the
level of serum TG decreased with the increasing of PPAR-α
and CPT-1 expression. These results indicated that PPAR-a
pathway contributed to the therapeutic role of 1, 25 (OH)
2D3 on diabetes-induced hepatic steatosis. Moreover, we
suggest that 1, 25 (OH) 2D3 may play as PPAR-α agonists
that could decrease plasma TG levels to modulate lipid me-
tabolism. Nevertheless, the detailed mechanism behind
PPAR-α up-regulation by 1, 25 (OH) 2D3 considered as
complex and remains unclear.
Recent studies have suggested that PPAR-α down-
regulation may facilitate the activity of hepatic pro-
inflammatory cytokines [47]. Devchand et al. [48] have
demonstrated that PPAR-α plays a role in acute inflam-
mation control by using the PPAR-α-deficient mice.
Thus, the PPAR-α signaling pathway may become a po-
tentially interesting target for anti-inflammatory drug
development. Furthermore, several studies have shown
that inflammation regulates expression of PPAR iso-
forms, transcriptional interference between PPAR-α
and NF-κ B occurs reciprocally, since NF-κ B can in-
hibit PPAR-α-mediated activation of a PPAR response
element-driven promoter [49]. In this study, we have
demonstrated that 1, 25 (OH) 2D3 can down-regulates
the expression of the NF-κ B up-regulates the expres-
sion of PPAR-α in liver, and the expression of NF-κ B
and PPAR-α were negatively correlated. Concordantly
with a previous report [47-49], we speculate that fur-
ther investigation of the molecular interaction between
NF-κ B and PPAR-α in liver may help to develop thera-
peutic approaches for the treatment of hepatic diseases
associated with diabetes mellitus.
In summary, our data provided some evidences that 1,
25 (OH) 2D3 can inhibit NF-κ B and its downstreaminflammatory cytokines expression and promote PPAR-α
and CPT-1 expression in liver of diabetic rat, which may
partly contribute to its protective effects for diabetic
liver injury. Further studies are required to identify how
1, 25 (OH) 2D3 can regulate the gene expression involved
in hepatic proinflammatory cytokines and lipid metabolism.
The relationship between vitamin D response element and
the direct impact of 1, 25 (OH) 2D3 on NF-κ B and PPAR-α
gene expression in liver may need further investigation.
Conclusion
This study links the effects of the 1, 25 (OH) 2D3 in
regulating proinflammatory cytokines and lipid metabol-
ism in a DM liver model. 1, 25 (OH) 2D3 significantly
changed liver functional characteristics and fatty acid
regulation, which may have been caused by its effects on
hepatic PPAR-α and proinflammatory cytokines.
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